Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Alessandro Del Conte"'
Autor:
Elisa De Carlo, Elisa Bertoli, Monica Schiappacassi, Brigida Stanzione, Alessandro Del Conte, Roberto Doliana, Michele Spina, Alessandra Bearz
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Over the past decade, molecular characterization has led to change the management of advanced non-small cell lung cancer (NSCLC) harboring driver mutations. Rearranged during transfection (RET) gene fusions, occurring in 1% to 2% of NSCLC, have emerg
Externí odkaz:
https://doaj.org/article/bba8322347704220a1e389f3fbdd3567
Autor:
Brigida Stanzione, Alessandro Del Conte, Elisa Bertoli, Elisa De Carlo, Alberto Revelant, Michele Spina, Alessandra Bearz
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11495 (2023)
ROS proto-oncogene 1 (ROS1) rearrangements occur in 0.9–2.6% of patients with non small cell lung cancer (NSCLC), conferring sensitivity to treatment with specific tyrosine-kinase inhibitors (TKI). Crizotinib, a first-generation TKI, was the first
Externí odkaz:
https://doaj.org/article/d711bbfafc3c4b85a9492091f37ff1a2
Autor:
Elisa Bertoli, Elisa De Carlo, Debora Basile, Diego Zara, Brigida Stanzione, Monica Schiappacassi, Alessandro Del Conte, Michele Spina, Alessandra Bearz
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 13, p 10803 (2023)
Tissue biopsy is essential for NSCLC diagnosis and treatment management. Over the past decades, liquid biopsy has proven to be a powerful tool in clinical oncology, isolating tumor-derived entities from the blood. Liquid biopsy permits several advant
Externí odkaz:
https://doaj.org/article/9ade8a1eee544518b75da88770f8a6e5
Autor:
Elisa De Carlo, Elisa Bertoli, Alessandro Del Conte, Brigida Stanzione, Eleonora Berto, Alberto Revelant, Michele Spina, Alessandra Bearz
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 12, p 6477 (2022)
The therapeutic landscape in patients with advanced non-small-cell lung cancer harboring oncogenic biomarkers has radically changed with the development of targeted therapies. Although lung cancers are known to frequently metastasize to the brain, on
Externí odkaz:
https://doaj.org/article/ef26a6e904894f0dbe66133d4241658a
Autor:
Anna Michelotti, Marco de Scordilli, Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Alessandra Bearz
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 12, p 6748 (2022)
Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a revolutionary change in the therapeutic scenario. The identification
Externí odkaz:
https://doaj.org/article/afd60f58b9064900ba9d5b8f5756ea06
Autor:
Alessandro Del Conte, Elisa De Carlo, Elisa Bertoli, Brigida Stanzione, Alberto Revelant, Manuela Bertola, Michele Spina, Alessandra Bearz
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 12, p 6832 (2022)
Patients with non-small cell lung cancer (NSCLC) develop bone metastasis (BoM) in more than 50% of cases during the course of the disease. This metastatic site can lead to the development of skeletal related events (SREs), such as severe pain, pathol
Externí odkaz:
https://doaj.org/article/99ff9329877648afbe754af448fce06f
Autor:
Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Brigida Stanzione, Alberto Revelant, Kelly Fassetta, Michele Spina, Alessandra Bearz
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 13, p 6936 (2022)
Osimertinib is currently the preferred first-line therapy in patients with non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutation and the standard second-line therapy in T790M-positive patients in progression
Externí odkaz:
https://doaj.org/article/b2efde60ec714a138443995f94784031
Autor:
Marco de Scordilli, Anna Michelotti, Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Alessandra Bearz
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 13, p 7222 (2022)
The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSCLC) is rapidly evolving. As already happened for the advanced disease, also early stages have entered the era of precision medicine, with molecular analysis and Progr
Externí odkaz:
https://doaj.org/article/5378efc9221a4730ae93a07519f0c82c
Autor:
Alessandra Bearz, Elisa De Carlo, Alessandro Del Conte, Michele Spina, Valentina Da Ros, Elisa Bertoli, Alberto Revelant, Brigida Stanzione, Umberto Tirelli
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 13, p 7322 (2022)
The severe prognosis linked with a lung cancer diagnosis has changed with the discovery of oncogenic molecularly driven subgroups and the use of tailored treatment. ALK-translocated advanced lung cancer is the most interesting model, having achieved
Externí odkaz:
https://doaj.org/article/5ac59ed6962e4484a60d6b9cc857fef9
Autor:
Mario Tamburrini, Dipti Gothi, Carlo Barbetta, Alessandro Del Conte, Sandro Sulfaro, Umberto Zuccon
Publikováno v:
Respiratory Medicine Case Reports, Vol 26, Iss , Pp 154-156 (2019)
A 45-year old man, chronic smoker with a pancoast tumor due to squamous cell carcinoma has been described. The initial diagnosis of lung carcinoma was based on a scant tissue so the exact cell typing was not possible. The initial treatment consisted
Externí odkaz:
https://doaj.org/article/d9d2e85e08c14670bee5b612bdedc692